Uncategorized
AstraZeneca’s camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca’s proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative metastatic breast cancer, dealing an early blow to the British pharma’s $5 billion peak sales plan.